Quoin Pharmaceuticals Ltd (QNRX) FinancialsQNRXFinancialQuoin Pharmaceuticals Ltd

Evaluating the bottom line, Quoin Pharmaceuticals Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -575.73%, provide a clear picture of how effectively QNRX converts its operational activities into shareholder value.

In the context of the broader market, QNRX competes directly with industry leaders such as IMRN and MBRX. With a market capitalization of $12.29M, it holds a significant position in the sector. When comparing efficiency, QNRX's gross margin of N/A stands against IMRN's 63.42% and MBRX's N/A. Such benchmarking helps identify whether Quoin Pharmaceuticals Ltd is trading at a premium or discount relative to its financial performance.

Quoin Pharmaceuticals has been experiencing significant net losses, with Q2 2026 reporting a net income of -5,371,042 USD. The company's current ratio is 1.76, indicating it has sufficient current assets to cover its liabilities, but the debt to equity ratio has been fluctuating, reaching 51.46% in Q2 2026.